ALKERMES | ALKS

ALKERMES traded at $26.16 this Wednesday March 22nd, decreasing $0.36 or 1.36 percent since the previous trading session. Looking back, over the last four weeks, ALKERMES lost 4.39 percent. Over the last 12 months, its price rose by 0.27 percent. Looking ahead, we forecast ALKERMES to be priced at 25.04 by the end of this quarter and at 22.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
26.10
Daily Change
-1.58%
Yearly
0.04%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Otsuka Holdings 3,958.00 40.00 1.02% -7.31%
AbbVie 153.90 -2.87 -1.83% -2.85%
Acadia Pharmaceuticals 18.91 -0.55 -2.80% -26.38%
Acorda Therapeutics 0.61 -0.01 -1.14% -66.03%
Amgen 230.08 -2.87 -1.23% -1.75%
Biogen 261.74 -4.41 -1.66% 24.86%
Bluebird Bio 4.37 -0.23 -5.00% -12.25%
BioMarin Pharmaceutical 90.52 -1.57 -1.70% 11.94%
Bristol-Myers Squibb 67.32 -0.19 -0.28% -5.69%
Coherus Biosciences 6.00 -0.10 -1.64% -52.04%
Gilead Sciences 77.79 -1.35 -1.71% 32.18%
Heron Therapeutics 2.01 -0.18 -8.24% -63.21%
Horizon Pharma 107.50 -1.73 -1.58% -0.91%
Ionis Pharmaceuticals 35.56 -0.06 -0.17% -0.31%
Intra Cellular Therapies 46.35 0.17 0.37% -22.10%
Jazz Pharmaceuticals 140.24 0.53 0.38% -11.50%
J&J 151.34 -2.55 -1.66% -13.19%
Eli Lilly 331.23 0.15 0.05% 16.55%
Merck & Co 104.61 -0.93 -0.88% 31.21%
Marinus Pharmaceuticals 6.19 -0.06 -0.88% -42.14%
Neurocrine Biosciences 96.12 -0.32 -0.33% 3.69%
Minerva Neurosciences 1.70 0.01 0.59% 115.22%
Nektar Therapeutics 0.82 -0.05 -5.58% -86.63%
Pfizer 40.10 -0.56 -1.38% -23.17%
Regeneron Pharmaceuticals 752.92 -6.84 -0.90% 12.51%
Revance Therapeutics 32.28 -0.51 -1.56% 64.95%
Teva Pharmaceutical Industries 8.83 0.03 0.34% 8.88%
Vertex Pharmaceuticals 298.41 -4.25 -1.40% 20.26%


ALKERMES
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.